Click here to get full coverage on Are Investors Undervaluing Axogen, Inc. (NASDAQ:AXGN) By 31%? - Yahoo Finance

Are Investors Undervaluing Axogen, Inc. (NASDAQ:AXGN) By 31%?  Yahoo Finance

Are Investors Undervaluing Axogen, Inc. (NASDAQ:AXGN) By 31%? - Yahoo Finance

Click here to get full coverage on AxoGen (NASDAQ:AXGN) Shares Down 3% - Here's What Happened - MarketBeat

AxoGen (NASDAQ:AXGN) Shares Down 3% - Here's What Happened  MarketBeat

AxoGen (NASDAQ:AXGN) Shares Down 3% - Here's What Happened - MarketBeat

Click here to get full coverage on Axogen (AXGN): Reassessing Valuation After FDA BLA Approval for AVANCE Nerve Allograft - Sahm

Axogen (AXGN): Reassessing Valuation After FDA BLA Approval for AVANCE Nerve Allograft  Sahm

Axogen (AXGN): Reassessing Valuation After FDA BLA Approval for AVANCE Nerve Allograft - Sahm

Click here to get full coverage on Why Is AXGN Stock Rising Today? - Stocktwits

Why Is AXGN Stock Rising Today?  Stocktwits

Why Is AXGN Stock Rising Today? - Stocktwits

Click here to get full coverage on Axogen (AXGN) Price Target Increased by 18.26% to 34.58 - Nasdaq

Axogen (AXGN) Price Target Increased by 18.26% to 34.58  Nasdaq

Axogen (AXGN) Price Target Increased by 18.26% to 34.58 - Nasdaq

Click here to get full coverage on Insider Sale: Director at $AXGN Sells 20,436 Shares - Quiver Quantitative

Insider Sale: Director at $AXGN Sells 20,436 Shares  Quiver Quantitative

Insider Sale: Director at $AXGN Sells 20,436 Shares - Quiver Quantitative

Click here to get full coverage on AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm - Business Wire

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm  Business Wire

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm - Business Wire

Click here to get full coverage on Axogen (NASDAQ: AXGN) secures FDA BLA approval for Avance biologic, U.S. launch expected in Q2 2026 - Stock Titan

Axogen (NASDAQ: AXGN) secures FDA BLA approval for Avance biologic, U.S. launch expected in Q2 2026  Stock Titan

Axogen (NASDAQ: AXGN) secures FDA BLA approval for Avance biologic, U.S. launch expected in Q2 2026 - Stock Titan

Click here to get full coverage on With 88% ownership of the shares, Axogen, Inc. (NASDAQ:AXGN) is heavily dominated by institutional owners - Yahoo Finance

With 88% ownership of the shares, Axogen, Inc. (NASDAQ:AXGN) is heavily dominated by institutional owners  Yahoo Finance

With 88% ownership of the shares, Axogen, Inc. (NASDAQ:AXGN) is heavily dominated by institutional owners - Yahoo Finance

Click here to get full coverage on Axogen (AXGN): Reassessing Valuation After FDA Biologics License Approval for AVANCE - Sahm

Axogen (AXGN): Reassessing Valuation After FDA Biologics License Approval for AVANCE  Sahm

Axogen (AXGN): Reassessing Valuation After FDA Biologics License Approval for AVANCE - Sahm

Click here to get full coverage on Canaccord Genuity Maintains Axogen (AXGN) Buy Recommendation - Nasdaq

Canaccord Genuity Maintains Axogen (AXGN) Buy Recommendation  Nasdaq

Canaccord Genuity Maintains Axogen (AXGN) Buy Recommendation - Nasdaq

Click here to get full coverage on Lindsey Marie Hartley Sells 14,812 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat

Lindsey Marie Hartley Sells 14,812 Shares of AxoGen (NASDAQ:AXGN) Stock  MarketBeat

Lindsey Marie Hartley Sells 14,812 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat

Click here to get full coverage on AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates - Yahoo Finance

AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates  Yahoo Finance

AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates - Yahoo Finance

Click here to get full coverage on $AXGN stock is up 8% today. Here's what we see in our data. - Quiver Quantitative

$AXGN stock is up 8% today. Here's what we see in our data.  Quiver Quantitative

$AXGN stock is up 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Assenagon Asset Management S.A. Grows Stake in AxoGen, Inc. $AXGN - MarketBeat

Assenagon Asset Management S.A. Grows Stake in AxoGen, Inc. $AXGN  MarketBeat

Assenagon Asset Management S.A. Grows Stake in AxoGen, Inc. $AXGN - MarketBeat

Click here to get full coverage on Axogen (NASDAQ:AXGN) shareholder returns have been strong, earning 161% in 3 years - Yahoo Finance

Axogen (NASDAQ:AXGN) shareholder returns have been strong, earning 161% in 3 years  Yahoo Finance

Axogen (NASDAQ:AXGN) shareholder returns have been strong, earning 161% in 3 years - Yahoo Finance

Click here to get full coverage on AxoGen (AXGN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

AxoGen (AXGN) Earnings Expected to Grow: Should You Buy?  Yahoo Finance

AxoGen (AXGN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Click here to get full coverage on AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance

AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates  Yahoo Finance

AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance

Click here to get full coverage on Are Medical Stocks Lagging AxoGen (AXGN) This Year? - Yahoo Finance

Are Medical Stocks Lagging AxoGen (AXGN) This Year?  Yahoo Finance

Are Medical Stocks Lagging AxoGen (AXGN) This Year? - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $AXGN Given $40 Price Target | AXGN Stock News - Quiver Quantitative

New Analyst Forecast: $AXGN Given $40 Price Target | AXGN Stock News  Quiver Quantitative

New Analyst Forecast: $AXGN Given $40 Price Target | AXGN Stock News - Quiver Quantitative

Click here to get full coverage on Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin - Yahoo Finance

Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin  Yahoo Finance

Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin - Yahoo Finance

Click here to get full coverage on Raymond James Slashes PT on Axogen (AXGN) to $20 From $21 - Yahoo Finance

Raymond James Slashes PT on Axogen (AXGN) to $20 From $21  Yahoo Finance

Raymond James Slashes PT on Axogen (AXGN) to $20 From $21 - Yahoo Finance

Click here to get full coverage on Should FDA Biologic Approval of AVANCE Nerve Scaffold Require Action From Axogen (AXGN) Investors? - Sahm

Should FDA Biologic Approval of AVANCE Nerve Scaffold Require Action From Axogen (AXGN) Investors?  Sahm

Should FDA Biologic Approval of AVANCE Nerve Scaffold Require Action From Axogen (AXGN) Investors? - Sahm

Click here to get full coverage on A Look at Axogen (AXGN) Valuation Following FDA Avance Delay and Securities Law Probe - Yahoo Finance

A Look at Axogen (AXGN) Valuation Following FDA Avance Delay and Securities Law Probe  Yahoo Finance

A Look at Axogen (AXGN) Valuation Following FDA Avance Delay and Securities Law Probe - Yahoo Finance

Click here to get full coverage on Axogen (AXGN) director Burke sells $403k in stock - Investing.com

Axogen (AXGN) director Burke sells $403k in stock  Investing.com

Axogen (AXGN) director Burke sells $403k in stock - Investing.com

Click here to get full coverage on Trading the Move, Not the Narrative: (AXGN) Edition - Stock Traders Daily

Trading the Move, Not the Narrative: (AXGN) Edition  Stock Traders Daily

Trading the Move, Not the Narrative: (AXGN) Edition - Stock Traders Daily

Click here to get full coverage on AxoGen, Inc. (NASDAQ:AXGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

AxoGen, Inc. (NASDAQ:AXGN) Given Consensus Recommendation of "Moderate Buy" by Analysts  MarketBeat

AxoGen, Inc. (NASDAQ:AXGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Click here to get full coverage on Amy Mcbride Wendell Sells 43,684 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat

Amy Mcbride Wendell Sells 43,684 Shares of AxoGen (NASDAQ:AXGN) Stock  MarketBeat

Amy Mcbride Wendell Sells 43,684 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat

Click here to get full coverage on AxoGen (NASDAQ:AXGN) Stock Price Up 5.4% - What's Next? - MarketBeat

AxoGen (NASDAQ:AXGN) Stock Price Up 5.4% - What's Next?  MarketBeat

AxoGen (NASDAQ:AXGN) Stock Price Up 5.4% - What's Next? - MarketBeat

Click here to get full coverage on $AXGN stock is up 21% today. Here's what we see in our data. - Quiver Quantitative

$AXGN stock is up 21% today. Here's what we see in our data.  Quiver Quantitative

$AXGN stock is up 21% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN - PR Newswire

Click here to get full coverage on Paul Thomas Sells 21,399 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat

Paul Thomas Sells 21,399 Shares of AxoGen (NASDAQ:AXGN) Stock  MarketBeat

Paul Thomas Sells 21,399 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat

Click here to get full coverage on New Analyst Forecast: $AXGN Given 'Buy' Rating - Quiver Quantitative

New Analyst Forecast: $AXGN Given 'Buy' Rating  Quiver Quantitative

New Analyst Forecast: $AXGN Given 'Buy' Rating - Quiver Quantitative

Click here to get full coverage on AxoGen (NASDAQ:AXGN) Director Sells $1,378,596.15 in Stock - MarketBeat

AxoGen (NASDAQ:AXGN) Director Sells $1,378,596.15 in Stock  MarketBeat

AxoGen (NASDAQ:AXGN) Director Sells $1,378,596.15 in Stock - MarketBeat

Click here to get full coverage on AxoGen (NASDAQ:AXGN) Insider Sells $609,125.57 in Stock - MarketBeat

AxoGen (NASDAQ:AXGN) Insider Sells $609,125.57 in Stock  MarketBeat

AxoGen (NASDAQ:AXGN) Insider Sells $609,125.57 in Stock - MarketBeat

Click here to get full coverage on FDA Pushes Axogen's Groundbreaking Nerve Graft Review to December Following New Manufacturing Data - Stock Titan

FDA Pushes Axogen's Groundbreaking Nerve Graft Review to December Following New Manufacturing Data  Stock Titan

FDA Pushes Axogen's Groundbreaking Nerve Graft Review to December Following New Manufacturing Data - Stock Titan

Click here to get full coverage on Axogen Inc (AXGN) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Progress Amid ... - Yahoo Finance

Axogen Inc (AXGN) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Progress Amid ...  Yahoo Finance

Axogen Inc (AXGN) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Progress Amid ... - Yahoo Finance

Click here to get full coverage on Michael Dale Sells 61,463 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat

Michael Dale Sells 61,463 Shares of AxoGen (NASDAQ:AXGN) Stock  MarketBeat

Michael Dale Sells 61,463 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat

Click here to get full coverage on Axogen (AXGN) Q2 Revenue Jumps 18% - Nasdaq

Axogen (AXGN) Q2 Revenue Jumps 18%  Nasdaq

Axogen (AXGN) Q2 Revenue Jumps 18% - Nasdaq

Click here to get full coverage on Axogen, Inc. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:AXGN) 2025-08-05 - Seeking Alpha

Axogen, Inc. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:AXGN) 2025-08-05  Seeking Alpha

Axogen, Inc. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:AXGN) 2025-08-05 - Seeking Alpha

Click here to get full coverage on Insider Sale: Director at $AXGN Sells 14,571 Shares - Quiver Quantitative

Insider Sale: Director at $AXGN Sells 14,571 Shares  Quiver Quantitative

Insider Sale: Director at $AXGN Sells 14,571 Shares - Quiver Quantitative

Click here to get full coverage on Insider Sale: Chief Innovation Officer of $AXGN Sells 1,137 Shares - Quiver Quantitative

Insider Sale: Chief Innovation Officer of $AXGN Sells 1,137 Shares  Quiver Quantitative

Insider Sale: Chief Innovation Officer of $AXGN Sells 1,137 Shares - Quiver Quantitative

Click here to get full coverage on Insider Selling: AxoGen (NASDAQ:AXGN) Director Sells 23,693 Shares of Stock - MarketBeat

Insider Selling: AxoGen (NASDAQ:AXGN) Director Sells 23,693 Shares of Stock  MarketBeat

Insider Selling: AxoGen (NASDAQ:AXGN) Director Sells 23,693 Shares of Stock - MarketBeat

Click here to get full coverage on Insider Sell: Marc Began Sells Shares of Axogen Inc (AXGN) - GuruFocus

Insider Sell: Marc Began Sells Shares of Axogen Inc (AXGN)  GuruFocus

Insider Sell: Marc Began Sells Shares of Axogen Inc (AXGN) - GuruFocus

Click here to get full coverage on Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined - Seeking Alpha

Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined  Seeking Alpha

Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined - Seeking Alpha

Click here to get full coverage on (AXGN) Volatility Zones as Tactical Triggers - Stock Traders Daily

(AXGN) Volatility Zones as Tactical Triggers  Stock Traders Daily

(AXGN) Volatility Zones as Tactical Triggers - Stock Traders Daily

Click here to get full coverage on AxoGen (NASDAQ:AXGN) Sets New 12-Month High - Here's What Happened - MarketBeat

AxoGen (NASDAQ:AXGN) Sets New 12-Month High - Here's What Happened  MarketBeat

AxoGen (NASDAQ:AXGN) Sets New 12-Month High - Here's What Happened - MarketBeat

Click here to get full coverage on Axogen (AXGN): Reassessing Valuation After FDA BLA Approval for AVANCE Nerve Allograft - simplywall.st

Axogen (AXGN): Reassessing Valuation After FDA BLA Approval for AVANCE Nerve Allograft  simplywall.st

Axogen (AXGN): Reassessing Valuation After FDA BLA Approval for AVANCE Nerve Allograft - simplywall.st

Click here to get full coverage on Axogen stock reaches 52-week high at 24.94 USD - Investing.com

Axogen stock reaches 52-week high at 24.94 USD  Investing.com

Axogen stock reaches 52-week high at 24.94 USD - Investing.com

Click here to get full coverage on $AXGN stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$AXGN stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$AXGN stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen (NASDAQ:AXGN) - Seeking Alpha

Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen (NASDAQ:AXGN)  Seeking Alpha

Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen (NASDAQ:AXGN) - Seeking Alpha

Click here to get full coverage on Why Is Axogen Stock Soaring Thursday? - Axogen (NASDAQ:AXGN) - Benzinga

Why Is Axogen Stock Soaring Thursday? - Axogen (NASDAQ:AXGN)  Benzinga

Why Is Axogen Stock Soaring Thursday? - Axogen (NASDAQ:AXGN) - Benzinga

Click here to get full coverage on Axogen, Inc. Reports Third Quarter 2025 Financial Results - GlobeNewswire

Axogen, Inc. Reports Third Quarter 2025 Financial Results  GlobeNewswire

Axogen, Inc. Reports Third Quarter 2025 Financial Results - GlobeNewswire

Click here to get full coverage on Jefferies Remains a Buy on AxoGen (AXGN) - The Globe and Mail

Jefferies Remains a Buy on AxoGen (AXGN)  The Globe and Mail

Jefferies Remains a Buy on AxoGen (AXGN) - The Globe and Mail

Click here to get full coverage on CCORF Maintains AxoGen(AXGN.US) With Buy Rating, Raises Target Price to $37 - 富途牛牛

CCORF Maintains AxoGen(AXGN.US) With Buy Rating, Raises Target Price to $37  富途牛牛

CCORF Maintains AxoGen(AXGN.US) With Buy Rating, Raises Target Price to $37 - 富途牛牛

Click here to get full coverage on Should FDA Biologic Approval of AVANCE Nerve Scaffold Require Action From Axogen (AXGN) Investors? - simplywall.st

Should FDA Biologic Approval of AVANCE Nerve Scaffold Require Action From Axogen (AXGN) Investors?  simplywall.st

Should FDA Biologic Approval of AVANCE Nerve Scaffold Require Action From Axogen (AXGN) Investors? - simplywall.st

Click here to get full coverage on Price-Driven Insight from (AXGN) for Rule-Based Strategy - Stock Traders Daily

Price-Driven Insight from (AXGN) for Rule-Based Strategy  Stock Traders Daily

Price-Driven Insight from (AXGN) for Rule-Based Strategy - Stock Traders Daily

Click here to get full coverage on Axogen, Inc. to Announce 2025 Second Quarter Financial Results on August 5, 2025 | AXGN Stock News - Quiver Quantitative

Axogen, Inc. to Announce 2025 Second Quarter Financial Results on August 5, 2025 | AXGN Stock News  Quiver Quantitative

Axogen, Inc. to Announce 2025 Second Quarter Financial Results on August 5, 2025 | AXGN Stock News - Quiver Quantitative

Click here to get full coverage on Composite Rating For Axogen Rises To 97 - Investor's Business Daily

Composite Rating For Axogen Rises To 97  Investor's Business Daily

Composite Rating For Axogen Rises To 97 - Investor's Business Daily

Click here to get full coverage on Axogen, Inc. (NASDAQ:AXGN) Is Expected To Breakeven In The Near Future - 富途牛牛

Axogen, Inc. (NASDAQ:AXGN) Is Expected To Breakeven In The Near Future  富途牛牛

Axogen, Inc. (NASDAQ:AXGN) Is Expected To Breakeven In The Near Future - 富途牛牛

Click here to get full coverage on (AXGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

(AXGN) as a Liquidity Pulse for Institutional Tactics  Stock Traders Daily

(AXGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Click here to get full coverage on Axogen Showcases Nerve Repair Vision at Goldman Sachs - Yahoo Finance

Axogen Showcases Nerve Repair Vision at Goldman Sachs  Yahoo Finance

Axogen Showcases Nerve Repair Vision at Goldman Sachs - Yahoo Finance

Click here to get full coverage on Axogen, Inc. Receives FDA Extension for Avance® Nerve Graft Biologics License Application Review - Quiver Quantitative

Axogen, Inc. Receives FDA Extension for Avance® Nerve Graft Biologics License Application Review  Quiver Quantitative

Axogen, Inc. Receives FDA Extension for Avance® Nerve Graft Biologics License Application Review - Quiver Quantitative

Click here to get full coverage on With 88% ownership in Axogen, Inc. (NASDAQ:AXGN), institutional investors have a lot riding on the business - simplywall.st

With 88% ownership in Axogen, Inc. (NASDAQ:AXGN), institutional investors have a lot riding on the business  simplywall.st

With 88% ownership in Axogen, Inc. (NASDAQ:AXGN), institutional investors have a lot riding on the business - simplywall.st

Click here to get full coverage on Axogen (AXGN) Considers Potential Sale Amid Takeover Proposal - GuruFocus

Axogen (AXGN) Considers Potential Sale Amid Takeover Proposal  GuruFocus

Axogen (AXGN) Considers Potential Sale Amid Takeover Proposal - GuruFocus

Click here to get full coverage on Is FDA Review Delay and Legal Scrutiny Altering the Investment Case for Axogen (AXGN)? - Sahm

Is FDA Review Delay and Legal Scrutiny Altering the Investment Case for Axogen (AXGN)?  Sahm

Is FDA Review Delay and Legal Scrutiny Altering the Investment Case for Axogen (AXGN)? - Sahm

Click here to get full coverage on When Can We Expect A Profit From Axogen, Inc. (NASDAQ:AXGN)? - simplywall.st

When Can We Expect A Profit From Axogen, Inc. (NASDAQ:AXGN)?  simplywall.st

AXGN

Price Chart

Key Statistics

Technicals

About AXGN

Latest News

Are Investors Undervaluing Axogen, Inc. (NASDAQ:AXGN) By 31%? - Yahoo Finance

AxoGen (NASDAQ:AXGN) Shares Down 3% - Here's What Happened - MarketBeat

Axogen (AXGN): Reassessing Valuation After FDA BLA Approval for AVANCE Nerve Allograft - Sahm

Advanced Charts

Top Gainers

Top Losers